- Home
- CKPT vs PBFS Comparison
CKPT vs PBFS Comparison
Compare CKPT & PBFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- PBFS
- Stock Information
- Founded
- CKPT 2014
- PBFS 1889
- Country
- CKPT United States
- PBFS United States
- Employees
- CKPT N/A
- PBFS N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- PBFS Banks
- Sector
- CKPT Health Care
- PBFS Finance
- Exchange
- CKPT Nasdaq
- PBFS Nasdaq
- Market Cap
- CKPT 335.9M
- PBFS 278.5M
- IPO Year
- CKPT 2017
- PBFS N/A
- Fundamental
- Price
- CKPT $4.04
- PBFS $11.26
- Analyst Decision
- CKPT Buy
- PBFS
- Analyst Count
- CKPT 3
- PBFS 0
- Target Price
- CKPT $4.33
- PBFS N/A
- AVG Volume (30 Days)
- CKPT 1.7M
- PBFS 16.3K
- Earning Date
- CKPT 05-09-2025
- PBFS 05-12-2025
- Dividend Yield
- CKPT N/A
- PBFS N/A
- EPS Growth
- CKPT N/A
- PBFS 11.77
- EPS
- CKPT N/A
- PBFS 0.76
- Revenue
- CKPT $41,000.00
- PBFS $88,118,000.00
- Revenue This Year
- CKPT $102,182.93
- PBFS N/A
- Revenue Next Year
- CKPT $351.71
- PBFS N/A
- P/E Ratio
- CKPT N/A
- PBFS $14.82
- Revenue Growth
- CKPT N/A
- PBFS 21.67
- 52 Week Low
- CKPT $1.38
- PBFS $8.76
- 52 Week High
- CKPT $4.50
- PBFS $12.20
- Technical
- Relative Strength Index (RSI)
- CKPT 63.60
- PBFS 44.04
- Support Level
- CKPT $3.94
- PBFS $10.60
- Resistance Level
- CKPT $4.06
- PBFS $11.46
- Average True Range (ATR)
- CKPT 0.05
- PBFS 0.43
- MACD
- CKPT -0.03
- PBFS -0.01
- Stochastic Oscillator
- CKPT 83.33
- PBFS 49.08
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.